Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 3:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1273–1296 of 4,667 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Respiratory Therapy Clear all
Completed Not applicable Interventional

Hepatitis C Alcohol Reduction Treatment

NCT02176980
View directory record Official record
Conditions
Hepatitis C, Chronic; AUD
Interventions
Brief alcohol counseling, Group and Individual Therapy Sessions
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 18, 2018 · Synced Oct 30, 2026, 3:35 PM EDT
Active, not recruiting Phase 3 Interventional

Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer

NCT01993810
View directory record Official record
Conditions
Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage III Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7
Interventions
Carboplatin, Cisplatin, Durvalumab, Etoposide, Paclitaxel, Pemetrexed Disodium, Photon Beam Radiation Therapy, Proton Beam Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration
Drug · Biological · Radiation + 1 more
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
30
States / cities
Jacksonville, Florida • Warrenville, Illinois • Baltimore, Maryland + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 30, 2026, 3:35 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer

NCT00033696
View directory record Official record
Conditions
Lung Cancer
Interventions
filgrastim, carboplatin, etoposide, paclitaxel, topotecan hydrochloride, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 120 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
51
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2016 · Synced Oct 30, 2026, 3:35 PM EDT
Completed Phase 3 Interventional Results available

A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype

NCT04718103
View directory record Official record
Conditions
Asthma
Interventions
GSK3511294, Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
41
States / cities
Alabaster, Alabama • Mobile, Alabama • Phoenix, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2024 · Synced Oct 30, 2026, 3:35 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

NCT03703297
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Durvalumab, Tremelimumab, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
34
States / cities
Tucson, Arizona • Santa Rosa, California • New Haven, Connecticut + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 30, 2026, 3:35 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure

NCT04311697
View directory record Official record
Conditions
Critical COVID-19 With Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS), Corona Virus Infection, Acute Lung Injury
Interventions
Aviptadil by intravenous infusion + standard of care, Normal Saline Infusion + standard of care
Drug
Lead sponsor
APR Applied Pharma Research s.a.
Other
Eligibility
18 Years to 100 Years
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
10
States / cities
Fullerton, California • Irvine, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Oct 30, 2026, 3:35 PM EDT
Completed No phase listed Observational

Impact of Monoclonal Antibody Treatment on Post-Acute COVID-19 Syndrome

NCT05013723
View directory record Official record
Conditions
Post-acute COVID-19 (PACS), or "long COVID" Syndrome
Interventions
Surveys
Other
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Nov 7, 2024 · Synced Oct 30, 2026, 3:35 PM EDT
Terminated Phase 2 Interventional Results available

Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds

NCT04240886
View directory record Official record
Conditions
Invasive Fungal Infections
Interventions
fosmanogepix
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
6
States / cities
Duarte, California • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 30, 2026, 3:35 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)

NCT05033080
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-121/TEZ/D-IVA, ELX/TEZ/IVA, IVA, Placebo (matched to VX-121/TEZ/D-IVA), Placebo (matched to ELX/TEZ/IVA), Placebo (matched to IVA)
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
435 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
69
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 61 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Oct 30, 2026, 3:35 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Anti-Platelets in Chronic Obstructive Pulmonary Disease

NCT05567562
View directory record Official record
Conditions
COPD, Emphysema, Emphysema or COPD
Interventions
dual anti-platelet therapy, Placebo
Combination Product · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 30, 2026, 3:35 PM EDT
Completed Phase 2 Interventional

Cisplatin and Irinotecan Followed by Carboplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer

NCT00072527
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, cisplatin, etoposide, irinotecan hydrochloride, radiation therapy
Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
76
States / cities
Lewes, Delaware • Newark, Delaware • Wilmington, Delaware + 56 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2016 · Synced Oct 30, 2026, 3:35 PM EDT
Active, not recruiting Phase 2 Interventional

Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone

NCT03040973
View directory record Official record
Conditions
Advanced Solid Tumors Which Are cMET-dependent
Interventions
Capmatinib, Nazartinib, Gefitinib, Osimertinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 30, 2026, 3:35 PM EDT
Active, not recruiting Phase 3 Interventional

Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer

NCT03793179
View directory record Official record
Conditions
Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Carboplatin, Computed Tomography, Magnetic Resonance Imaging, Pembrolizumab, Pemetrexed, Positron Emission Tomography
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1081
States / cities
Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 694 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 30, 2026, 3:35 PM EDT
Completed Phase 3 Interventional

A Randomized, Unblinded Trial of Zidovudine Versus ddC in the Treatment of Patients Status Post PCP Who Received Long-Term Zidovudine Therapy in Protocol ACTG 002

NCT00000682
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Zalcitabine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1992
U.S. locations
5
States / cities
Los Angeles, California • San Diego, California • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 30, 2026, 3:35 PM EDT
Completed Phase 2 Interventional Results available

Carboplatin, Pemetrexed Disodium, and Bevacizumab for Patients With Stage III or IV Non-Small Cell Lung Cancer Who Are Light/Never Smokers

NCT01344824
View directory record Official record
Conditions
Lung Cancer
Interventions
bevacizumab, carboplatin, erlotinib hydrochloride, pemetrexed disodium
Biological · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
4
States / cities
Asheville, North Carolina • Chapel Hill, North Carolina • New Bern, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2017 · Synced Oct 30, 2026, 3:35 PM EDT
Completed Phase 2 Interventional Results available

Radiation Therapy in Treating Patients With Extensive Stage Small Cell Lung Cancer

NCT01055197
View directory record Official record
Conditions
Lung Cancer
Interventions
Prophylactic Cranial Irradiation, Radiation Therapy
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
108
States / cities
Tucson, Arizona • Fresno, California • Sacramento, California + 87 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Oct 30, 2026, 3:35 PM EDT
Terminated Phase 1Phase 2 Interventional

ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers

NCT05616624
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Non-small Cell Lung Cancer, Small-cell Lung Cancer, Small Cell Lung Carcinoma
Interventions
ADI-PEG 20, Gemcitabine, Docetaxel
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Chicago, Illinois • St Louis, Missouri • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 30, 2026, 3:35 PM EDT
Completed Not applicable Interventional Results available

RADx-UP Phase 3D (Oregon Saludable: Juntos Podemos)

NCT05910879
View directory record Official record
Conditions
Health Behavior, Health Care Utilization, Vaccine Hesitancy
Interventions
Self-Affirmation Implementation Intentions (SAII) Intervention, Promotores de Salud (Health Education)
Behavioral
Lead sponsor
University of Oregon
Other
Eligibility
18 Years and older
Enrollment
625 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 30, 2026, 3:35 PM EDT
Recruiting Phase 1 Interventional

Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors

NCT07443020
View directory record Official record
Conditions
Malignant Pleural Effusion, Malignant Mesothelioma, Pleural Effusion, Malignant, Metastasis to Pleura
Interventions
locally manufactured adoptive cellular therapy (ACT) product, Interleukin-2 (IL-2)
Biological · Drug
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
18 Years to 79 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2038
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 30, 2026, 3:35 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/II NabPaclitaxel, Paclitaxel&Carboplatin w RTX Followed by Consolidation in Patients w Favorable Prognosis Inoperable Stage IIIA/B NSCLC

NCT01757288
View directory record Official record
Conditions
STAGE IIIA/B NSCLC / INOPERABLE LUNG CANCER
Interventions
NAB-PACLITAXEL, PACLITAXEL
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
5
States / cities
Rochester, New York • Pittsburgh, Pennsylvania • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 30, 2026, 3:35 PM EDT
Completed Phase 2 Interventional Results available

Convalescent Plasma in the Treatment of COVID 19

NCT04343261
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), COVID, Coronavirus
Interventions
Convalescent Plasma
Biological
Lead sponsor
Trinity Health Of New England
Other
Eligibility
18 Years to 90 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Oct 30, 2026, 3:35 PM EDT
Completed Phase 2 Interventional Results available

Stereotactic Body Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Can Be Removed By Surgery

NCT00551369
View directory record Official record
Conditions
Lung Cancer
Interventions
SBRT
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
19
States / cities
Birmingham, Alabama • Berkeley, California • Carmichael, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Oct 30, 2026, 3:35 PM EDT
Not listed No phase listed Observational

Creation of Home-based Asthma Real-World Measures With Mobile Health Study

NCT04462224
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 85 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Oct 30, 2026, 3:35 PM EDT
Completed Phase 1 Interventional

Autologous Redirected RNA Meso-CIR T Cells

NCT01355965
View directory record Official record
Conditions
Malignant Pleural Mesothelioma
Interventions
Autologous T cells
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 19, 2017 · Synced Oct 30, 2026, 3:35 PM EDT